Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Author Archives: Alexis BERNARD

You are here:
  1. Home
  2. Article author Alexis BERNARD

AB Science webcast of January 28, 2025

2025By Alexis BERNARDJanuary 29, 2025

28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025

Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

2025By Alexis BERNARDJanuary 24, 2025

24/01/2025 – AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

AB Science will participate in the Biomed Forum investors conference

2025By Alexis BERNARDJanuary 22, 2025

22/01/2025 – AB Science announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors, that will take place on February 4, 2025, in Paris

Summary of the webcast held on December 16, 2024

2024By Alexis BERNARDDecember 17, 2024

17/12/2024 – AB Science provides a summary of the webcast held on December 16, 2024

AB Science webcast of December 16, 2024

2024By Alexis BERNARDDecember 16, 2024

16/12/2024 – Presentation of the AB Science webcast held on December 16, 2024

Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

2024By Alexis BERNARDDecember 11, 2024

11/12/2024 – AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

2024By Alexis BERNARDOctober 28, 2024

28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

2024By Alexis BERNARDOctober 17, 2024

17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis

Revenues for the first half of 2024 and update on AB Science’s activities

2024By Alexis BERNARDOctober 10, 2024

10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities

AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros

2024By Alexis BERNARDOctober 9, 2024

09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024

←12345…
6789101112131415161718192021222324
25→
AB Science
© AB Science – All right reserved
Go to Top